Merck & Co., Inc. (NYSE:MRK) Stock Bumped Up to "Hold" by Zacks Research

Merck & Co., Inc. logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research upgraded Merck from “strong sell” to “hold.” Overall analyst sentiment remains more positive, with a “Moderate Buy” consensus and an average price target of $155.74.
  • Merck reported quarterly EPS of $2.49, beating the $2.09 consensus estimate, while revenue of $18.09 billion also exceeded expectations and rose 4.7% year over year.
  • Executive Vice President Richard Deluca sold 58,185 shares, reducing his holdings by 34%; insiders collectively own 0.17% of the company’s stock.
  • Five stocks we like better than Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Tuesday, Zacks reports.

A number of other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Merck & Co., Inc. from $165.00 to $175.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Freedom Broker increased their target price on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the company a "hold" rating in a report on Monday, November 2nd. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an "overweight" rating in a research report on Friday, September 4th. Scotiabank boosted their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, September 29th. Finally, Barclays boosted their price target on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an "overweight" rating in a research note on Monday, October 26th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and an average price target of $155.74.

Read Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $137.75 on Tuesday. The company has a 50 day moving average of $145.73 and a 200 day moving average of $129.11. The stock has a market cap of $339.59 billion, a P/E ratio of 142.01, a P/E/G ratio of 6.57 and a beta of 0.13. Merck & Co., Inc. has a 12 month low of $93.90 and a 12 month high of $156.92. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm had revenue of $18.09 billion for the quarter, compared to analysts' expectations of $17.33 billion. During the same quarter last year, the firm posted $2.58 EPS. The company's revenue was up 4.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.

Insider Activity

In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the firm's stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the transaction, the executive vice president owned 112,955 shares of the company's stock, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.17% of the company's stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its position in Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the period. State Street Corp lifted its holdings in shares of Merck & Co., Inc. by 0.8% during the 3rd quarter. State Street Corp now owns 121,422,392 shares of the company's stock valued at $17,745,131,000 after buying an additional 1,009,136 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Merck & Co., Inc. by 2.3% during the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Merck & Co., Inc. by 8.3% in the 3rd quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company's stock worth $6,059,345,000 after buying an additional 3,183,169 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after buying an additional 2,919,780 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are a few of the latest headlines about MRK:

  • Positive Sentiment: Merck raised its quarterly dividend 3.5%, from $0.85 to $0.88 per share, equivalent to $3.52 annually. The increase may appeal to income-focused investors. Merck Announces First-Quarter 2027 Dividend
  • Positive Sentiment: A comparison with Bristol Myers Squibb characterized Merck as the stronger investment, citing its stock performance, oncology position, pipeline expansion and diversified growth drivers. Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
  • Negative Sentiment: Reports noted that EVP Richard Deluca sold 58,185 shares, reducing his holdings by 34%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. Insider Selling: Merck EVP Sells Shares

About Merck & Co., Inc.

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Recommended Stories

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines